A NOVEL APPROACH FOR CANCER THERAPY

APIM Therapeutics AS is a Norwegian biotech company developing novel first-in-class peptide drugs targeting the PCNA/APIM stress switch, a novel intervention point within the DNA Damage Response (DDR) pathway. This approach, based on ground-breaking research by Prof. Otterlei and co-workers at the University of Science and Technology, NTNU, Trondheim, allows the potentiation of the action of >25 clinical drugs across multiple cancer indications. ATX-101, the company’s current lead, has shown strong preclinical proof-of-efficacy in animal models of bladder, breast, multiple myeloma, AML and prostate cancer in cooperation with several anti-cancer drugs. Having concluded GLP safety & toxicology studies, ATX-101 is currently at the pre-CTA stage.

APIM Therapeutics has recruited EUR 6M from public and private sources since early 2010; the latest transaction was concluded in January 2016. Major current investors include: Sarsia Seed, Birk Venture, Ro Invest and Norsk Innovasjonskapital III. ATX-101 will be entering first-in-man studies in 2018; the planned clinical phase I/IIa trial will assess safety, (preliminary) efficacy and pharmacokinetic properties of ATX-101 in advanced cancer patients (all comers) treated with intravenously administered ATX-101.

APIM Therapeutics expects to close its first-in-man allowing financing round in November 2017.

APIM THERAPEUTICS VALUE PROPOSITION

THERAPEUTIC APPROACH

• Novel anti-cancer therapeutic approach targeting PCNA and cell stress responses using proprietary peptide drugs in combination with clinically relevant anti-cancer drugs (chemotherapeutic and targeted agents)

THE TARGET - PCNA

• Proliferating Cell Nuclear Antigen (PCNA) is a key regulator of DNA replication, repair, cell cycle control, signal transduction, metabolism and apoptosis
• Controls cell responses to stress e.g. DNA Damage Response stress induced by anti-cancer treatment
• Allows cancer-specific tumor cell elimination even in the absence of cell division

THE LEAD - ATX-101

• Short-chained peptide comprising a novel PCNA-interacting Peptide Motif termed APIM
• Induces cell apoptosis in selected cancer cells when given as a single agent and cancer cell hypersensitivity to >25 different anti-cancer agents (chemotherapy, radiation, targeted agents) when given in combination.
• Potent combinatorial anti-tumor activity in bladder, breast, myeloma, leukemia and prostate cancer animal models; currently in pre-IND/CTA stage. A phase I/IIa clinical trial is planned to start in 2018.

INTELLECTUAL PROPERTY

• International PCT patent application currently in national phases; granted in several countries
• Freedom-to-Operate (FTO) analysis positive

PEOPLE

• International business and development team with strong experience in cancer drug development

MANAGEMENT

Kostas Alevizopoulos, CEO
+41 78 752 7002
kalevizo@apimtherapeutics.com
www.apimtherapeutics.com

Marit Otterlei, CSO
+47 928 89 422
marit.otterlei@ntnu.no
www.apimtherapeutics.com